
The Supreme Court questioned why a proposed 30% trade-margin cap should be restricted to cancer drugs rather than extended to all essential medicines and medical products.
The Centre informed the bench that the margin cap on non-scheduled cancer drugs is expected to reduce retail prices by 20% to 70%.
The bench directed the Centre until October 27 to work out the modalities for capping medicine prices.